'A Spoonful of Regulation Helps the Medicine Go Down': The Changing Face of Medicine Regulation

Social Theory and Health

Volumn 5, Issue 2, 2007, Pages 145-160

  Edgley, Alison ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Abraham; Medicine regulation; Rx to OTC; Statins; Switching

Indexed keywords

EID: 51249140444     PISSN: 14778211     EISSN: 1477822X     Source Type: Journal    
DOI: 10.1057/palgrave.sth.8700095     Document Type: Article

References (45)

1. Abraham J (1995). Science, Politics and the Pharmaceutical Industry. UCL/St Martins Press: London
2. Abraham J (2002). The pharmaceutical industry as a political player. The Lancet 360: 1489-1502
3. Abraham J (2005). Regulating the drugs industry transparently. BMJ 331: 528-529
4. Abraham J, Davis C (2005a). A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Social Science and Medicine 61: 881-892
5. Abraham J, Davis C (2005b). Regulation of Innovative Pharmaceuticals in the EU and the US. Final Report to ESRC Project L218252001
6. Abraham J, Lewis G (1998). Secrecy and transparency of medicines licensing in the EU. Lancet 352: 480-482
7. Abraham J, Lewis G (1999). Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval? Social Science and Medicine 48: 1655-1667
8. Abraham J, Lewis G (2002). Citizenship, medical expertise and the capitalist regulatory state in Europe. Sociology 36: 67-88
9. Abraham J, Reed T (2003). Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both? Social Science and Medicine 57: 195-204
10. Anon (2003). Lifting advertising ban could lead to more switches to pharmacy medicines. The Pharmaceutical Journal 271: 198
11. Baxter J (ed) (2004). Keynote Market Report, OTC Pharmaceuticals, 11th edition, May 2004
12. Bond C (2001). POM to P-Implications for practice pharmacists. Primary Care Pharmacy 2: 5-7
13. Braithwaite J (1984). Corporate Crime in the Pharmaceutical Industry. London: Routledge, Kegan Paul
14. Bunney R (2004). Has the lesson of HRT been learnt before mass prescribing of statins to 40% of the adult population? BMJ, http://bmj.bmjjournals.com/cgi/eletters/328/7436/400 (accessed 5 May 2004)
15. Busfield J (2006). Pills, power, people: sociological understandings of the pharmaceutical industry. Sociology 40: 297-314
16. Department of Health (1996). Doctor/patient partnership campaign
17. Department of Health (2000). The NHS Plan: a plan for investment, a plan for reform
18. Department of Health (2004) Heart drug available without a prescription, http://www.dh/gov/uk/PublicationsAndStatistics/PressReleasesNotices 2004/0186 (accessed 18 May 2004)
19. Edgley A (2002). The Social and Political Thought of Noam Chomsky. Routlege: London
20. Edgley A, Bissell P, James V (2003). Conflict and collaboration between professions and state: the case of nurse prescribing in the UK and USA, Conference paper, British Sociological Society Medical Sociology Group: York
21. Francis S-A, Barnett N, Denham M (2005). Switching of prescription drugs to over-the-counter status: is it a good thing for the elderly? Drugs and Aging 22: 5 pp 361-370 (10)
22. Department of Health (2005). Nurse and Pharmacist Prescribing Powers Extended. http://www.dh.gov.uk/Home/fs/en (accessed 15.11.05)
23. Gibson L (2004). Move to sell statins over the counter raises concerns. BMJ 328: 1221
24. House of Common Health Committee (2005). The influence of the pharmaceutical industry 22 March 2005, http://www.parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 20 February 2006)
25. Isles CG, Paterson JR (2000). Identifying patients at risk for coronary heart disease: implications from trials of lipid lowering drug therapy. BMJ 321: 971-972
26. Jessop N (2003). Global pharmaceutical parallel trade: can it ever happen? Pharmiweb 15 October 2003, accessed 7 May 2004
27. Mann S (2004). Interview with Vice President Research and Development, Europe. Johnson and Johnson 2 August 2004, unpublished
28. Mann S, Cottrell J (2004). No benefit in primary prevention trials? The Pharmaceutical Journal 272: 804
29. Marshall TP (2004). Why statins? BMJ http://bmj.bmjjournals.com/cgi/eletters/328/7436/400 (accessed 5 May 2004)
30. Merton RK (1936). The unintended consequences of purposive social action. American Sociological Review 1: 894
31. MHRA (2005). Legal status and reclassification. Licensing of Medicines, http://www.mhra.gov.uk/home/idcplg?IdcService=SS-GET-PAGE&nodeId=107
32. Moran M (1999). Governing the Health Care State: A Comparative Study of the United Kingdom, and the United States and Germany. Manchester University Press: Manchester
33. Moran M, Wood B (1993). States, Regulation and the Medical Profession. Open University Press: Buckingham
34. Noerreslet M, Larsen JB, Traulsen JM (2005). The medicine user-lost in translation? Analysis of the official political debate prior to the deregulation of the Danish medicine distribution system. Social Science and Medicine 61: 1733-1740
35. PAGB (2004). Recent Regulatory Developments Affecting the OTC Sector. http://www.pagb.co.uk/pagb/primarysections/selfcare/regulatoryinselfcare.htm (accessed 8 June 20050)
36. Perry G, Mansell P (2000). RX-to-OTC: The Way Forward for the Global Pharmaceutical Industry? Informa Publishing Group Ltd: London
37. Pignone M, Philips C, Mulrow C (2000). Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Monthly Journal of the Association of Physicians 93: 567-574
38. Raithatha N, Smith RD (2004). Paying for statins. BMJ 328: 400-402
39. Reid J (2003). Heart drug could be available in High Street pharmacies. Department of Health Press Release 2003/0463 17 November 2003 (accessed 18 May 2004)
40. Rodrigues LL (2003). Corporatism, liberalism and the accounting profession in Portugal since 1755
41. Journal of Accounting Historians 6(June), http://www.findarticles.com/p/articles/mi-qa3657/is-200306/ai-n9301506/print (accessed 21 July 2005)
42. Scrip Reports (2000). Direct-to-Consumer Advertising: Changing the Face of the Pharmaceutical Marketing. Morpace Pharma Group Ltd: Massachusetts
43. Soller RW (1999). The over the counter scientific/Regulatory Paradigm. Drug Information Journal 33: 799-804
44. Timmins N (2004). Ministers set rules for medicines regulators. Financial Times Friday November 12, 2004
45. Zwillich T (2005). Panel Rejects Over-the-Counter Cholesterol Drug. http://dailynews.att.net/cgi-bin/health?e=pub&dt=common&cat=cholesterol&st=cholesterol105234&src=webmd (accessed 20 February 2006).